These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22977140)

  • 1. EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats.
    Wang JL; Liu YL; Li Y; Dai WB; Guo ZM; Wang ZH; Zhang Q
    Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):7348-57. PubMed ID: 22977140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
    Haghiralsadat F; Amoabediny G; Naderinezhad S; Nazmi K; De Boer JP; Zandieh-Doulabi B; Forouzanfar T; Helder MN
    Pharm Res; 2017 Dec; 34(12):2891-2900. PubMed ID: 29110283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.
    Guo Z; He B; Yuan L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Int J Pharm; 2015 Sep; 493(1-2):380-9. PubMed ID: 26004003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CNV model.
    Liu HA; Liu YL; Ma ZZ; Wang JC; Zhang Q
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(7):4789-94. PubMed ID: 21519028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted treatment of choroidal neovascularization using integrin-mediated sterically stabilized liposomes loaded with combretastatin A4.
    Ma L; Liu YL; Ma ZZ; Dou HL; Xu JH; Wang JC; Zhang X; Zhang Q
    J Ocul Pharmacol Ther; 2009 Jun; 25(3):195-200. PubMed ID: 19456253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
    Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
    Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
    Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
    Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of targeted PDT and anti-VEGF therapy for rat CNV by RGD-modified liposomal photocyanine and sorafenib.
    Wang JL; Xi Y; Liu YL; Wang ZH; Zhang Q
    Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):7983-9. PubMed ID: 24204046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
    Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
    Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas.
    Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q
    Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model.
    Zhou R; Mazurchuk R; Straubinger RM
    Cancer Res; 2002 May; 62(9):2561-6. PubMed ID: 11980650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
    Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
    J Control Release; 2005 Oct; 107(2):262-75. PubMed ID: 16125816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
    Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
    Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin.
    Fan Y; Du W; He B; Fu F; Yuan L; Wu H; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2013 Mar; 34(9):2277-88. PubMed ID: 23290525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
    Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
    J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.
    Haghiralsadat F; Amoabediny G; Naderinezhad S; Zandieh-Doulabi B; Forouzanfar T; Helder MN
    Int J Nanomedicine; 2018; 13():3853-3866. PubMed ID: 30013340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
    Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
    Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disaccharide-modified liposomes and their in vitro intracellular uptake.
    Song CK; Jung SH; Kim DD; Jeong KS; Shin BC; Seong H
    Int J Pharm; 2009 Oct; 380(1-2):161-9. PubMed ID: 19635539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.